Announcements

20FEB

Removal of Component(s) – RYZB

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Thursday, February 22, 2024, RYZB will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On December 26, 2023, RayzeBio, Inc. announced that it would be acquired by Bristol Myers for $62.50/share in cash.
10DEC

Semi-Annual Reconstitution (Preliminary) - December 2023

LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index   The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Monday, December 18, 2023.  All positions will be equally weighted, with weights determined as of the closing prices on Thursday, December 14, 2023.  The preliminary changes are summarized below. LifeSci Biotechnology Clinical Trials Index (107 components as adjusted) Additions (17 stocks): ALPN, APGE, BEAM, BLTE, CABA, MGNX, NMRA, OLMA, ORIC, RYZB, SANA, SLNO, SLRN, SRRK, SYRE, TNGX, VERA Deletions (21 stocks): ABUS, ALDX, ARQT, ATAI, AVIR, BTAI, CERE, DSGN, ERAS, EWTX, FATE, FGEN, KOD, MCRB, MRSN, MRTX,
03NOV

Removal of Component(s) – PNT, ICPT

  LifeSci Biotechnology Clinical Trials Index LifeSci Biotechnology Products Index               Effective at the market close on Monday, November 6, 2023, the following changes will be made the LifeSci Biotechnology Indexes:   PNT will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On October 3, 2023, Point Biopharma Global announced it would be acquired by Eli Lilly and Company for $12.50/share in cash.   ICPT will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On September 26, 2023, Intercept
20SEP

Removal of Component(s) – RETA

LifeSci Biotechnology Products Index Effective at the market close on Thursday, September 21, 2023, RETA will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On July 28, 2023, Reata Pharmaceuticals announced that it would be acquired by Biogen Inc. for $172.50/share in cash.
07AUG

Removal of Component(s) – DICE

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Tuesday, August 8, 2023, DICE will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On June 20, 2023, DICE Therapeutics announced that it would be acquired by Eli Lilly for $48.00/share in cash.
14JUN

Semi-Annual Reconstitution (Final) - June 2023

LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index Index Semi-Annual Reconstitution (Final)   The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Friday, June 16, 2023.  All positions will be equally weighted, with weights determined as of the closing prices on Wednesday, June 14, 2023.  The preliminary changes are summarized below. LifeSci Biotechnology Clinical Trials Index (115 components as adjusted) Additions (15 stocks): ALDX, AMAM, ARDX, BMEA, CBAY, ETNB, EXAI, GPCR, IRON, LQDA, MLTX, MLYS, PHAT, TERN, VKTX Deletions (21 stocks): ACET, AFMD, ALT, ALVR, ATRA, CARA, CCCC, CDXS, IMAB, INKT, INO, KZR, NGM, NKTX, NUVB, RPTX, SGMO
26APR

Removal of Component(s) – MYOV

LifeSci Biotechnology Products Index Effective at the market close on Wednesday, April 26, 2023, PRVB will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On March 13, 2023, Provention Bio announced that it would be acquired by Sanofi for $25.00/share in cash.
27FEB

Removal of Component(s) – MYOV

LifeSci Biotechnology Products Index Effective at the market close on Tuesday, February 28, 2023, MYOV will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On October 23, 2022, Myovant Sciences announced that it would be acquired by Sumitomo Pharma for $27.00/share in cash.
17FEB

Removal of Component(s) – CINC

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Tuesday, February 21, 2023, CINC will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On January 9, 2023, CinCor Pharma, Inc. announced that it would be acquired by AstraZeneca for $26.00/share in cash plus a non-tradeable contingent value right of up to $10.00.  The tender offer is expected to expire in late February 2023.
13FEB

Removal of Component(s) – SRNE

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Monday, February 13, 2023, SRNE will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On February 13, 2023, Sorrento Therapeutics indicated it had filed for Chapter 11 bankruptcy. As a result, SRNE no longer qualifies for inclusion in the Index.
14DEC

Semi-Annual Reconstitution (Final) - December 2022

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Friday, December 16, 2022.  All positions will be equally weighted, with weights determined as of the closing prices on Wednesday, December 14, 2022.  The final changes are summarized below. LifeSci Biotechnology Clinical Trials Index (123 components as adjusted) Additions (15 stocks): ACLX, ALLK, ALT, ALVR, BHVN, CINC, COGT, DYN, FDMT, IMTX, NUVL, PLRX, SMMT, VERV, VRDN Deletions (12 stocks): ATHA, FHTX, GHRS, GOSS, IVVD, MGTX, PHAT, PRLD, RLMD, TIL, VXRT (no longer fit market cap and/or trading volume criteria) IMGN (being moved to Products Index
19OCT

Removal of Component(s) – CCXI

Effective at the market close on Wednesday, October 19, CCXI will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On August 4, 2022, ChemoCentryx, Inc. agreed to be acquired by Amgen for $52.00 per share in cash.
13JUN

Semi-Annual Reconstitution (Final) - June 2022

  LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index Index Semi-Annual Reconstitution (Final)   The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Thursday, June 16, 2022.  All positions will be equally weighted, with weights determined as of the closing prices on Tuesday, June 14, 2022.  The final changes are summarized below. LifeSci Biotechnology Clinical Trials Index (121 components as adjusted) Additions (8 stocks): DSGN, EQRX, FHTX, LYEL, PCVX, PNT, SRRA, VTYX   Deletions (66 stocks): ACIU, ADAP, AKBA, ALDX, ALGS, ALLK, ALVR, AMTI, ANNX, AUTL, BCAB, CGEN, CLVS, CMRX, CNTA, COGT, CRIS, CRTX, CTMX, CUE, CVM, DTIL, EPIX,
13DEC

Semi-Annual Reconstitution (Final) - December 2021

Index Semi-Annual Reconstitution (Final) December 13, 2021   The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Thursday, December 16, 2021.  All positions will be equally weighted, with weights determined as of the closing prices on Tuesday, December 14, 2021.  The preliminary changes, subject to modification, are summarized below.   LifeSci Biotechnology Clinical Trials Index (180 components as adjusted) Additions (21 stocks): ABUS, ACET, ADGI, ATAI, AUTL, CNTA, CRBU, DAWN, DICE, ERAS, EWTX, FULC, GHRS, GRPH, IMGO, KNTE, KZR, ROIV, RXRX, TIL, VBIV   Deletions (34 stocks): ADVM, ALBO, ANVS, APLT, ARDX, ATNX, AVRO, BCEL, BDTX, BOLT, CDAK, CRDF,
03NOV

Removal of Component(s) – KDMN

  Effective at the market close on Thursday, November 4, KDMN will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On September 8, 2021, Kadmon Holdings, Inc. agreed to be acquired by AstraZeneca plc for $9.50 per share in cash.